# FDA recall D-0177-2020

> **Dr. Reddy's Laboratories, Inc.** · Class II · drug recall initiated 2019-10-01.

## Product

Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 71713-203-02), b.)95 count bottles (NDC 71713-203-05)  (Thirty Madison) OTC.

## Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

## Distribution

Product was distributed to major distributors throughout the United States who may have further distributed the product.

## Key facts

- **Recall number:** D-0177-2020
- **Recalling firm:** Dr. Reddy's Laboratories, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Completed
- **Initiation date:** 2019-10-01
- **Report date:** 2019-11-13

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Princeton, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0177-2020

## Citation

> AI Analytics. FDA recall D-0177-2020. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-0177-2020. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*